

\_\_\_\_\_

Result No.	Score		Query Match	Length	DB	ID	Description
1	4069	100.0	788	22	AA039095	Human polypeptide	
2	4069	100.0	788	23	AAE23718	Human GNK interact	
3	4060	99.8	857	24	ABP59215	Human drug metaboli	
4	4047	99.5	820	22	AA040881	Human polypeptide	
5	2427	59.6	518	22	AA025938	Human protein sequ	
6	2089	51.3	435	22	AA075454	Human colon cancer	
7	1815	44.6	371	21	AA057103	Human prostate can	
8	882.5	21.7	852	22	AB058175	Drosophila melanoc	
9	354	8.7	90	22	AA005809	Human polypeptide	



25-APR-2000; 2000US-0552317.  
09-JUL-2000; 2000US-0598042.  
09-JUL-2000; 2000US-0620312.  
03-AUG-2000; 2000US-0653450.  
14-SEP-2000; 2000US-0662191.  
19-OCT-2000; 2000US-0693036.  
29-NOV-2000; 2000US-0727344.  
(HYSE-) HYSEQ INC.  
Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
WPI; 2001-442253/47.  
P-FSDB; AAM39095.  
Novel nucleic acids and polypeptides, useful for treating disorders  
such as central nervous system injuries -  
Claim 1; SEQ ID NO 454; 10078pp; English.  
The invention relates to human nucleic acids (AA157798-AA161369) and  
the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
immunosuppressant and cytostatic activity. The polynucleotides are useful  
in gene therapy. A composition containing a polypeptide or polynucleotide  
of the invention may be used to treat diseases of the peripheral nervous  
system, such as peripheral nervous injuries, peripheral neuropathy and  
localised neuropathies and central nervous system diseases, such as  
Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
utilisation of the activities such as: immune system suppression,  
activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
assays for receptor activity, arthritis and inflammation, leukaemias and  
C.N.S disorders.  
Note: The sequence data for this patent did not form part of the printed  
specification.  
Sequence 3964 BP; 1067 A; 867 C; 1037 G; 993 T; 0 other;

174	Db	ATGGAGCGTCCCTGGAGAAAGATAGCAGACCCACGTTAGCTGAATGGGAAAAACATTG	233
61	QY	AAGGAGGCAGTGAAGATGCTTGGAGGACAGTCCAGAGAAGAACAGAAAGAGAAAATGGAAG	120
234	Db	AAGGAGGCAGTGAAGATGCTTGGAGGACAGTCCAGAGAAGAACAGAAAGAGAAAATGGAAG	293
121	QY	AAGCTCATATCCGGAGATATCCAGGCCACTCCAGGCGAGTGGCGAAGATATGGTGAGC	180
294	Db	AAGCTCATATCCGGAGATATCCAGGCCACTCCAGGCGAGTGGCGAAGATATGGTGAGC	353
181	QY	ATCCTCCAGTTAGTTCAGAACTCATGTCATGGAGATGAAGATGAGGAGCCCCAGAGCCCC	240
354	Db	ATCCTCCAGTTAGTTCAGAACTCATGTCATGGAGATGAAGATGAGGAGCCCCAGAGCCCC	413
241	QY	AGAATCCAAAAATATCGAGAACAAAGCTCATATGGCTTTGTTGGACAATAGTCTGGGAGCT	300
414	Db	AGAATCCAAAAATATCGAGAACAAAGCTCATATGGCTTTGTTGGACAATAGTCTGGGAGCT	473
301	QY	TATATTTCAACTCTGCACAAAGAGAGCTCAGAAAACCTTACACTAGGATACTTTCAGAT	360
474	Db	TATATTTCAACTCTGCACAAAGAGAGCTCAGAAAACCTTACACTAGGATACTTTCAGAT	533
361	QY	ACCACCTTATGGCTATGCAGAAATTTTCAGATATGAAAATGGGTGTCCTATTTTCCACGAA	420
534	Db	ACCACCTTATGGCTATGCAGAAATTTTCAGATATGAAAATGGGTGTCCTATTTTCCACGAA	593

